Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Impax Laboratories Inc    IPXL

News SummaryMost relevantAll newsSector newsTweets 

Impax Laboratories Inc : Impax Laboratories to Present at the UBS Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
05/20/2013 | 01:35pm CET

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Investor Relations and Corporate Communications

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
01/12DJCigna Drops Coverage of Mylan's EpiPen for Cheaper Generic -- Update
01/12 IMPAX LABORATORIES : Bragar Eagel & Squire, P.C. Reminds Investors of a Class Ac..
01/12 IMPAX LABORATORIES : to Present at 35th Annual J.P. Morgan Healthcare Conference
01/11 IMPAX LABORATORIES : CVS Drops Price for EpiPen Competitor
01/11 IMPAX LABORATORIES, INC. (NASDAQ : IPXL) Files An 8-K Regulation FD Disclosure
01/11 IMPAX LABORATORIES INC : Regulation FD Disclosure, Financial Statements and Exhi..
01/10 IMPAX ASSET MANAGEMENT : Receives Strong Inflows In First Quarter
01/09 IMPAX LABORATORIES INC : FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LL..
01/09 IMPAX LABORATORIES INC : DEADLINE ALERT: Lundin Law PC Announces Securities Clas..
01/08 IMPAX LABORATORIES INC : Faruqi & Faruqi, LLP Encourages Investors Who Suffered ..
More news
Sector news : Pharmaceuticals - NEC
08:49aDJBayer Joins Jobs Parade -- WSJ
01:56aDJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says -- 2nd Update
12:05aDJAllergan Admits to Disclosure Violations During Valeant Bid
01/17 Allergan to pay $15 million over failing to disclose merger talks
01/17DJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/17 Impax Laboratories Stock To Rise On New Catalyst
01/13 SANOFI : Key Threats In 2017 And Beyond
01/12 CVS Health to sell Impax Labs' generic epinephrine autoinjector for $109.99
01/11 Cigna plays hardball with Mylan over EpiPen, drops coverage in favor of Impax..
01/05 Impax Laboratories - Management Has Destroyed A Lot Of Value, Risks Might Not..
Financials ($)
Sales 2016 846 M
EBIT 2016 144 M
Net income 2016 -126 M
Debt 2016 560 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 12,17
EV / Sales 2016 1,74x
EV / Sales 2017 1,41x
Capitalization 912 M
More Financials
Duration : Period :
Impax Laboratories Inc Technical Analysis Chart | IPXL | US45256B1017 | 4-Traders
Full-screen chart
Technical analysis trends IMPAX LABORATORIE...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 16
Average target price 18,5 $
Spread / Average Target 50%
Consensus details
EPS Revisions
More Estimates Revisions
J. Kevin Buchi President, Chief Executive Officer & Director
Robert L. Burr Chairman
Andrew Schaschl Senior Vice President-Global Operations
Bryan M. Reasons Chief Financial Officer & Senior VP-Finance
Vishal K. Gupta CSO, Senior Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.30%312 507
ROCHE HOLDING LTD.1.29%200 476
PFIZER INC.-1.29%194 551
NOVARTIS AG-2.70%185 185
MERCK & CO., INC.4.43%169 509
More Results